Today: 30 June 2026
Browse Category

NYSE:NVO 17 October 2025 - 8 November 2025

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the board toward Pfizer’s revised agreement. Novo responded that it would not increase its offer further, effectively bowing out. Reuters+1
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued at up to $10 billion. Metsera’s board cited legal and regulatory certainty in favoring Pfizer’s revised terms, while Novo Nordisk said it will not raise its competing proposal and is exiting the race. The merger is expected to close shortly after Metsera’s Nov. 13 special shareholder meeting, pending customary approvals. Reuters+1
8 November 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Summary: Novo Nordisk’s U.S.-listed shares traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift volumes over time. Investors are also watching a court decision that favored Novo in its bid for obesity biotech Metsera and closely reading this week’s Q3 update and guidance cut. Investopedia+3Reuters+3Novo Nordisk+3 By late morning U.S. time, NVO changed hands near $45.42, down ~2.3% on the day, within a $45.15–$46.26 range. Earlier in Europe, NOVO‑B in Copenhagen fell as much as 3.7%. The move follows Thursday’s White House‑brokered pricing framework for GLP‑1s. Reuters+1
7 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC, NVO traded around $47.30, down ~2.4% on the day. The company confirmed a Medicare Part D pilot beginning in 2026, lower U.S. prices in Medicare/Medicaid and cash channels, and a three‑year tariff exemption—and flagged a low single‑digit drag to 2026 global sales growth. GlobeNewswire
6 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven by two big headlines: a White House pricing agreement that expands access to GLP‑1 drugs across Medicare/Medicaid and a new direct‑to‑consumer channel, and a $10 billion bidding battle with Pfizer for obesity‑drug startup Metsera.
6 November 2025
·
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1
6 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs that demand growth is slowing and profitability is coming under pressurereuters.com. This abrupt shift in sentiment has been fueled by multiple challenges converging at once. Intensifying competition, pricing pressures, and even copycat drugs have combined to erode the previously sky-high expectations for Novo’s obesity franchisestocktwits.comreuters.com. The result: what was recently a steady success story has turned into what one analyst called a “chaotic” battle to defend Novo’s weight-loss drug leadershipstockanalysis.comstockanalysis.com. Investors, who bid Novo’s market capitalization to record levels in 2023, are now reeling from a string of disappointing updates in 2025.
5 November 2025
···
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alonereuters.comreuters.com. The share price is now hovering in the low $70sreuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emergedprnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major news: both Pfizer and Novo Nordisk submitted sweetened acquisition offers for Metsera on November 4, escalating their bidding warreuters.comreuters.com. Upon word that Metsera’s board favored Novo’s higher bid – and that a Delaware judge would allow the bidding contest to proceed freely, rather than blocking it at Pfizer’s request – traders piled into the stock, driving it up over 20% intradayreuters.comreuters.com. By the close, Metsera was up roughly +$12.5 on the day, around $73 per sharereuters.com, as the market began pricing in the possibility of an ~$86/share takeover by Novo or a counteroffer near that range.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings. From a chart perspective, Pfizer has clear support around the low-$20s – investors stepped in at ~$21 during 2025’s sell-offs, likely viewing the dividend yield as too attractive at those levels. On the upside, $28–$30 is a resistance zone, as rallies in 2024 and 2025 fizzled out there amid broader market weakness and company-specific news. A decisive break above $28 could signal a bullish trend change, but that may require tangible
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com. Pfizer, by contrast, has no obesity blockbuster drug of its own. In September it agreed to buy Metsera for up to $7.3 billion in order to jumpstart a presence in the roughly $150 billion obesity marketreuters.com. Its long-awaited annual results showed strong profits and a bumped-up full-year forecast, driven by cost cuts and steady core salesreuters.comreuters.com. But Pfizer immediately lost any lead when Novo swooped in.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensusreuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecastsstocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates. Encouraged by the quarter’s results, Pfizer raised its full-year 2025 earnings guidance for the second consecutive quarterreuters.com. The company now projects adjusted EPS of $3.00 to $3.15, signaling management’s growing confidence in the businessnasdaq.com. “We raised and narrowed our full-year 2025 adjusted diluted EPS guidance, underscoring confidence in our ability to deliver strong results,” stated Pfizer CFO David Denton in the earnings releasenasdaq.com. Notably, Pfizer maintained its full-year revenue forecast of $61–$64 billion, indicating that while profits are expected to improve, the top-line outlook remains unchangednasdaq.com. Wall Street’s current consensus falls in the middle of these rangesnasdaq.com, so Pfizer’s guidance essentially aligns with expectations on sales and slightly raises the earnings bar.
4 November 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir Technologies delivered a record third quarter, easily topping analyst expectations on both revenue and profit. The company’s revenue jumped 63% year-over-year to $1.18 billion, with adjusted earnings of $0.21 per share – well above estimates of about $0.17investopedia.com. CEO Alex Karp credited booming demand for Palantir’s Artificial Intelligence Platform, especially among commercial customers. U.S. commercial revenue more than doubled to $397 million, outpacing even robust growth in government contractsinvestopedia.com. Karp hailed the commercial business as an “absolute juggernaut” and lauded the company’s “otherworldly” AI-driven growth in a letter to investorsinvestopedia.com. On the back of these results, Palantir raised its guidance for the third time this year. It now forecasts Q4 2025 revenue of $1.327–$1.331 billion, dramatically above the ~$1.18 billion consensusinvesting.cominvestopedia.com. Full-year 2025 revenue is expected to reach ~$4.4 billion, up from prior guidance of ~$4.15 billioninvestopedia.com. This bullish outlook underscores Palantir’s momentum in the red-hot AI software arena. “They keep raising the bar for themselves,” observed Gil Luria, D.A. Davidson’s tech research chief, who called Palantir “by far the best software company” in its categorystockanalysis.com.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation and regulatory/legal risks. Community “fair value” estimates vary widely due to uncertaintysimplywall.st. Key analysts maintain Holds in light of decelerating growth and competition, though they acknowledge solid subscription volumes and expanding offeringstipranks.com. Bottom line: Hims & Hers is front-running the latest GLP-1 craze by marketing a “microdose” treatment, betting it can carve out a niche in preventive metabolic carenews.hims.comtipranks.com. Medical experts see both potential and pitfallsmedicalnewstoday.comnews.hims.com. Investors will be watching its Nov. 3 earnings for any sign that these new services boost subscriber growth or cross-selling, against a backdrop of intense industry competition. With consensus targets only modestly above current levelstipranks.com, the stock’s future hinges on execution across weight loss, men’s and women’s health, and how regulators treat compounded GLP-1 therapies. In Dr. Primack’s words: “microdosing is an
3 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bidreuters.com. This move comes just days after the foundation coup at Novoreuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respondts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately denounced Novo’s counterbid as “reckless” and vowed to defend the original agreementreuters.com. Observers note Novo carefully included the contingent CVRs and claims it adhered to the “no raid” clause in its agreement with Pfizerreuters.com, so the fight may end up in arbitration if no private settlement is reached. Metsera specializes in obesity therapeutics beyond the current GLP-1 trend. Its lead drug MET-097i is designed for once-monthly dosing – potentially boosting convenience and tolerabilityreuters.com. A Phase 2b trial of MET-097i showed up to ~14.1% weight loss, results that experts have hailed as “remarkable”reuters.comts2.tech. Its second program, MET-233i, is an oral agent mimicking the hormone amylin, a different weight-control pathwayreuters.com. None of these drugs are
31 October 2025
····
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash plus up to $22.50 in contingent paymentssec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatmentsec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wingsec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with an unsolicited offer valuing Metsera at up to $9 billion. Novo’s proposal is $56.50 per share cash at signing plus up to $21.25 in contingent value rightsprnewswire.com. The Metsera board declared Novo’s bid a “Superior Company Proposal”, triggering a four-day window for Pfizer to respondprnewswire.com. Pfizer immediately denounced the move: a Pfizer press release called Novo’s bid “reckless” and warned it could “suppress competition” in obesity drugsmarkets.ft.com.
30 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of the company’s ambition. In recent acquisitions of non-obesity assets, he said Novo was showing a “relentless ambition to move faster, go further”ts2.tech. The Metsera bid follows a sweeping boardroom shake-up at Novo, where its largest shareholder demanded faster action in the U.S. marketreuters.com. Now Novo is doubling down, essentially offering a higher price to hijack Pfizer’s deal and expand its obesity pipeline.
30 October 2025
····
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coveragecontractpharma.comgxpnews.net; GxP Newsgxpnews.netgxpnews.net; The Medicine Maker/Conexiantconexiant.comconexiant.com; GlobeNewswireglobenewswire.com; Evaluate Pharma forecastevaluate.comevaluate.com; Reutersreuters.com; TechStock² / TS2 Techts2.techts2.tech; TS2 Techts2.techts2.tech.
28 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on the key U.S. market to revive sales” reuters.com reuters.com. Former CEO Lars Rebien Sørensen is set to take over as chair for 2–3 years reuters.com. Trading reacted sharply. Novo’s Copenhagen-listed shares briefly plunged 6% on Oct. 17 when President Trump said he would force Ozempic’s price much lower reuters.com, and fell another ~3% on Oct. 22 when the board shake-up was announced reuters.com. One analyst likened the foundation’s move to a “structural governance reset” aimed at better aligning the board with Novo’s new consumer-driven strategy reuters.com. Portfolio manager Markus Manns observed that the Foundation simply wants “a fresh set of eyes, new energy to support management” – in other words, more influence over Novo’s direction reuters.com. Manns added that the board changes are intended to inject more consumer expertise: newcomers include executives with retail and digital backgrounds, reflecting a push to tap the fast-growing self-pay and online markets reuters.com
22 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levelsreuters.comreuters.com and miles below the late-2024 peakreuters.comreuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has intensified: U.S. rival Eli Lilly – maker of diabetes drug Mounjaro – has aggressively entered the obesity fray with Zepbound. Lilly’s dual-acting GLP-1 drug showed such strong results that it “overtook Wegovy in weekly prescriptions in the U.S.” earlier this yearreuters.com. Although Wegovy scripts have since accelerated and narrowed Lilly’s leadreuters.com, Novo no longer has the market to itself. Moreover, a wave of clinics and compounding pharmacies in the U.S. began selling “copycat” semaglutide formulations at lower costs, nibbling at Novo’s demandreuters.com.
17 October 2025
··
1 … 4 5 6 7

Stock Market Today

  • Cramer's 10 Big Movers for June 30
    June 30, 2026, 9:20 AM EDT. Jim Cramer flagged 10 top market moves for Tuesday, June 30. S&P 500 and Nasdaq futures were flat as both indexes looked set for their best quarters since Q2 2020, up about 14% and 20%. Comcast jumped after Deutsche Bank upgraded the stock following its NBCUniversal spin-off. Applied Materials and Lam Research both got price target hikes because of ongoing chip shortages. Wells Fargo lifted its price target on AMD as the company stands out in CPU and GPU spaces. Morgan Stanley raised Alphabet to an upgrade on optimism over Google Cloud. Piper Sandler put a buy on Capital One, though with some caution. Logitech got a downgrade on weaker demand. AeroVironment soared more than 30% after drone results beat expectations. The moves point to selective strength in tech and financial names.
Go toTop